A phase 2a exploratory study of TAR-0520 gel in prevention of Hand and Foot Syndrome

Condition studied

Capecitabine-induced hand and foot syndrome

Investigational medicinal product(s)

Eligibility

Primary endpoint

Incidence of Adverse Events, Adverse Events of Special Interest and Serious Adverse Events

Endpoint detail

Incidence and severity of NCI-CTCAE (Palmar-plantar erythrodysesthesia syndrome) grading by oncologist